Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination

Launched by ANRS, EMERGING INFECTIOUS DISEASES · Jul 4, 2022

Keywords

ClinConnect Summary

The ANRS 0146s NovaaTen study is a clinical trial that aims to understand how well the yellow fever vaccine works in people who are living with HIV, ten years after they received the vaccine. Researchers want to see if those who had the vaccine still have a good immune response compared to a group of people who do not have HIV. This is important because yellow fever can be a serious disease, especially for those with weakened immune systems.

To be eligible for the trial, participants must have been part of a previous study called the ANRS EP46 Novaa trial. This includes 40 HIV-positive individuals who have been on stable treatment for their HIV for at least a year and have good health markers. Additionally, 20 HIV-negative individuals from travel medicine consultations can also participate. Participants will need to agree to be monitored according to the study's guidelines and sign consent forms. The trial is not yet recruiting, so those interested will have to wait for more information on when it will begin.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Subjects included in the ANRS EP 46 NOVAA trial:
• • 40 HIV positive subjects from consultations for infectious diseases and travel medicine centers at Saint-Louis, Cochin-Pasteur and Bichat hospitals (on HAART for at least one year and not modified in the 3 months preceding the pre-inclusion visit, CD4 \> 350/mm3 and a viral load \<50 copies / mL for at least 6 months).
• • 20 HIV negative subjects from the consultation of travelers from Saint-Louis, Bichat and Cochin-Pasteur hospitals.
• • Subjects agreeing to be monitored according to the terms of the protocol.
• • Subjects affiliated to a Social Security scheme or beneficiaries of such a scheme.
• • Signature of informed consent.
• Exclusion Criteria:
• • Non-volunteers for the 10-year follow-up
• • Subject under curatorship, guardianship or safeguard of justice.